Eli Lilly (LLY) Reports 56% Revenue Growth, Raises 2026 Outlook
Published on · Source: finance.yahoo.com
AI Summary
Summarized by AI from the source belowEli Lilly and Co (NYSE:LLY) announced Q1 2026 results, with adjusted earnings per share at $8.55, exceeding analyst estimates of $6.66 to $6.97. Revenue reached $19.8 billion, surpassing expectations of $17.4 billion to $17.8 billion, indicating a 56% year-over-year increase. The company raised its 2026 revenue outlook to between $82 billion and $85 billion, up from $80 billion to $83 billion. This growth is primarily driven by increased prescription volumes for its GLP-1 medications, despite lower pricing realizations, and the recent FDA approval of Foundayo is expected to further expand access to treatments.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Eli Lilly and Company (LLY)
Eli Lilly is a major pharmaceutical company known for diabetes and obesity treatments and a broad drug pipeline.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier LLY news
- Premarket Stocks: Meta, Eli Lilly, Caterpillar and Amazon Update
- Eli Lilly (LLY) Reports Q1 Earnings, Raises 2026 Revenue Outlook by $2B
- Eli Lilly (LLY) Reports $12.9 Billion in GLP-1 Drug Sales
- Novartis (NVS) drug trials target Lp(a) for heart disease prevention
- Eli Lilly (LLY) Plans $7B Acquisition, P/E at 40 Amid Growth
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
